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Purpose: To evaluate the efﬁcacy and safety of ranibizumab 0.5 mg in adult patients with macular edema
(ME) resulting from any cause other than diabetes, retinal vein occlusion, or neovascular age-related macular
degeneration.
Design: A phase 3, 12-month, double-masked, randomized, sham-controlled, multicenter study.
Participants: One hundred seventy-eight eligible patients aged 18 years.
Methods: Patients were randomized 2:1 to receive either ranibizumab 0.5 mg (n ¼ 118) or sham (n ¼ 60) at
baseline and month 1. From month 2, patients in both arms received open-label individualized ranibizumab
treatment based on disease activity. A preplanned subgroup analysis was conducted on the primary end point on
5 predeﬁned baseline ME etiologies (inﬂammatory/post-uveitis, pseudophakic or aphakic, central serous cho-
rioretinopathy, idiopathic, and miscellaneous).
Main Outcome Measures: Changes in best-corrected visual acuity (BCVA; Early Treatment Diabetic Reti-
nopathy Study letters) from baseline to month 2 (primary end point) and month 12 and safety over 12 months.
Results: Overall, 156 patients (87.6%) completed the study. The baseline characteristics were well balanced
between the treatment arms. Overall, ranibizumab showed superior efﬁcacy versus sham from baseline to month
2 (least squares mean BCVA, þ5.7 letters vs. þ2.9 letters; 1-sided P ¼ 0.0111), that is, a treatment effect (TE)
of þ2.8 letters. The mean BCVA gain from baseline to month 12 was 9.6 letters with ranibizumab. The TE at month
2 was variable in the 5 predeﬁned etiology subgroups, ranging from >5-letter gain to 0.5-letter loss. The safety
ﬁndings were consistent with the well-established safety proﬁle of ranibizumab.
Conclusions: The primary end point was met and ranibizumab showed superiority in BCVA gain over sham in
treating ME due to uncommon causes, with a TE of þ2.8 letters versus sham at month 2. At month 12, the mean
BCVA gain was high (9.6 letters) in the ranibizumab arm; however, the TE was observed to be variable across the
different etiology subgroups, reaching a >1-line TE in BCVA in patients with ME resulting from inﬂammatory
conditions/post-uveitis or after cataract surgery. Overall, ranibizumab was well tolerated with no new safety
ﬁndings up to month 12. Ophthalmology 2017;-:1e13 ª 2018 by theAmerican Academy of Ophthalmology. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Supplemental material available at www.aaojournal.org.Macular edema (ME) is characterized by vascular leakage
and accumulation of ﬂuid resulting from pathologic changes
in the retinal vasculature and may result in irreversible
structural damage and permanent loss of vision.1 The
underlying pathophysiology of ME is multifactorial,
complex, and poorly understood.1e3 Thus, ME remains
one of the major therapeutic challenges in ophthalmology.
In many cases, ME involves abnormally increased vascular
endothelial growth factor (VEGF) levels in the retina that
cause disruption of the blooderetinal barrier, followed by
increased accumulation of ﬂuid within the intraretinal layers
of the macula.1ª 2018 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by Elsevier Inc.The most common causes for ME in the working-age
population are diabetic retinopathy and retinal vein occlu-
sion (RVO).2,3 These ocular conditions can lead to severe
and irreversible vision loss if left untreated.1e6 Less
frequent retinal vascular disorders, inﬂammatory disorders,
choroidal vascular diseases, inherited retinal dystrophies,
intraocular tumors, and optic nerve abnormalities also cause
ME and their prevalence varies worldwide.2,3 Currently,
there is no health authorityeapproved therapy for treating
ME caused by conditions other than diabetic retinopathy,
RVO, or neovascular age-related macular degeneration
(nAMD). Different available treatment options for ME1https://doi.org/10.1016/j.ophtha.2017.12.002
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roidal anti-inﬂammatory drugs, topical corticosteroids,
verteporﬁn photodynamic therapy (vPDT), laser photoco-
agulation, and intravitreal corticosteroids along with the
off-label use of anti-VEGF agents.3,7e12 Considering the
well-established efﬁcacy and safety of ranibizumab for the
treatment of visual impairment resulting from diabetic ME
(DME) and ME after RVO,13e24 ranibizumab (Lucentis;
Novartis Pharma AG, Basel, Switzerland, and Genentech,
Inc, South San Francisco, CA) as an anti-VEGF agent could
be beneﬁcial also for the treatment of ME secondary to
uncommon ocular conditions.
Previously published reports assessed the potential of
anti-VEGF agents like bevacizumab and ranibizumab in the
treatment of ME resulting from uncommon causes
like uveitis, pseudophakia or aphakia, central serous
chorioretinopathy (CSC), radiation retinopathy, and
others.9,25e36 The treatment effect observed with anti-VEGF
agents was variable7,25e29,32,36; hence, there was need for a
long-term randomized clinical trial to establish the efﬁcacy
and safety of anti-VEGF in these uncommon conditions.
The PROMETHEUS study (a complete listing of the
members of the study group is available in Appendix 1,
available at www.aaojournal.org) was designed to evaluate
the efﬁcacy and safety of an individualized ranibizumab
0.5-mg dosing regimen, based on disease activity, in adult
patients with visual impairment resulting from ME associ-
ated with uncommon causes other than DME, nAMD, and
RVO.
Methods
Study Design
The PROMETHEUS study was a 12-month, phase 3, randomized,
double-masked, sham-controlled multicenter study conducted
across 19 countries (Appendix 2, available at
www.aaojournal.org). The study was initiated in October 2013
and was completed in September 2015. The study protocol was
reviewed and approved by an independent ethics committee or
institutional review board for each center and the study was
conducted in accordance with the tenets of the Declaration of
Helsinki. Patients provided written informed consent at screening
and a re-consent after the implementation of the ﬁrst protocol
amendment. The study is registered with Clinicaltrials.gov (iden-
tiﬁer, NCT01846299).
Patients
The study population consisted of patients 18 years of age or older
with visual impairment due to active ME secondary to causes other
than diabetic retinopathy, nAMD, or RVO. The inclusion criteria
were diagnosis of active chronic ME (>3 months) conﬁrmed by
the presence of 1 of the following 3 criteria: (1) posterior pole
changes compatible with active ME observed by fundus ophthal-
moscopy, biomicroscopy, and fundus photography; (2) leakage
from ME documented by ﬂuorescein angiography (FA); and (3)
intraretinal ﬂuid or cysts seen by OCT and best-corrected visual
acuity (BCVA) between 24 Early Treatment Diabetic Retinopathy
Study (ETDRS) letters or more and 83 ETDRS letters or fewer.
Patients were excluded if they demonstrated ME associated
with diabetic retinopathy, nAMD, or RVO; retinal angiomatous
proliferation lesions in patients 50 years of age or older; any type of2systemic advanced, severe, or unstable disease or its treatment that
could interfere with primary or secondary outcome evaluations, or
both; uncontrolled systemic inﬂammation or infection related
directly to the underlying causal disease of ME; active diabetic
retinopathy and active ocular or periocular infectious disease or
active severe intraocular inﬂammation (intraocular pressure
25 mmHg); history of laser photocoagulation with involvement
of the macular area, vPDT, and vitreoretinal surgery and intra-
vitreal implants at any time; and use of anti-VEGF agents and
intravitreal steroids within 6 months of the baseline visit (inclusion
and exclusion criteria are listed in detail in Appendix 3, available at
www.aaojournal.org).
Randomization and Treatment
Eligible patients were randomized in a 2:1 ratio to either of 2
treatment arms (ranibizumab 0.5 mg or sham) at baseline using
interactive response technology. Although patients received open-
label therapy from month 2 onward, the examiners who assessed
the efﬁcacy outcomes were masked and not allowed to perform any
other tasks that would unmask them to the treatment received by
the patients through the entire study period of 12 months.
Patients in the ranibizumab arm received ranibizumab 0.5 mg at
baseline followed by an individualized pro re nata (PRN) treatment
regimen based on evidence of disease activity (judged clinically or
based on morphologic features or imaging) as judged and assessed
by the investigator at each individual follow-up visit (Fig S1,
available at www.aaojournal.org). All the patients were
monitored for disease activity by the masked investigator (details
of masking are available in Appendix 4, available at
www.aaojournal.org) at each monthly visit.
Patients in the sham arm received a sham injection at baseline
and another sham injection PRN at month 1. From month 2, sham
patients could be switched to open-label treatment with PRN
ranibizumab 0.5 mg based on the evidence of disease activity (with
no mandatory ranibizumab injection at month 2 in case of no
disease activity). Thus, as of month 2, patients in both treatment
arms could receive open-label PRN ranibizumab.
Rescue Medication
Patients could receive rescue treatment, as per routine clinical
practice, only at month 1, and patients could be treated with laser
photocoagulation or periocular treatments (e.g., sub-Tenon’s, ret-
robulbar, or subconjunctival corticosteroid) at the discretion of the
masked investigator if the patient had a visual acuity (VA) loss of
more than 5 letters from baseline to month 1 because of disease
activity. Further details are provided in Appendix 5 (available at
www.aaojournal.org).
Objectives
The primary objective was to demonstrate that individualized
ranibizumab 0.5 mg had superior efﬁcacy compared with sham
treatment in adult patients with visual impairment due to ME with
respect to the change in BCVA from baseline to month 2. Pre-
planned subgroup analyses were conducted on the primary end
point for the following predeﬁned baseline ME etiologies inﬂam-
matory or post-uveitis, pseudophakic or aphakic, CSC, idiopathic
retinopathy or retinochoroidopathy, and miscellaneous (causes that
did not ﬁt into the other ME etiology subgroups and were insuf-
ﬁciently frequent to form a separate subgroup). The secondary
objectives were to evaluate (1) mean change in BCVA
from baseline to month 12, (2) mean change in central subﬁeld
thickness (CSFT) and central subﬁeld volume (CSFV) from
baseline to month 12 and from baseline to months 2 and 12 by
baseline ME cause subgroups, (3) overall treatment exposure of
Staurenghi et al  Ranibizumab for ME of Uncommon Causesranibizumab up to month 11 and by baseline ME etiology sub-
groups, and (4) the overall safety of ranibizumab treatment and by
baseline ME etiology subgroups up to month 12. The exploratory
objectives were to evaluate (1) mean change in BCVA from
baseline to months 2 and 12 by baseline ME etiology, (2) mean
change in CSFT and CSFV from baseline to months 2 and 12 by
baseline ME etiology, (3) the proportion of patients with absence
of ME by baseline ME cause at months 2 and 12, and (4) the
proportion of patients with absence of intraretinal ﬂuid, cysts, and
subretinal ﬂuid by baseline ME etiology at months 2 and 12.
Efﬁcacy and Safety Assessments
The study eye was assessed at all visits and assessments were
performed before administering the study treatment, if applicable.
Best-Corrected Visual Acuity. BCVA was assessed at all
study visits by a certiﬁed VA examiner using ETDRS charts at an
initial distance of 4 m, reduced to 1 m, if necessary.
OCT. OCT was performed by certiﬁed site personnel at every
study visit using either time-domain OCT equipment (1 site used
the Zeiss Stratus) or spectral-domain OCT equipment (e.g., Cirrus,
Spectralis, Topcon, Nidek, Optovue, and Opko). To ensure a
standardized evaluation of the quantitative (e.g., CSFT and CSFV)
and qualitative (e.g., ME, cysts, and intraretinal and subretinal
ﬂuid) anatomic parameters and their change over time as end
points, the raw images were forwarded to a central reading center
(CRC; Bern Photographic Reading Center, Bern, Switzerland).
Thickness at all visits was measured between Bruch’s membrane
and the inner limiting membrane, and the same device was used for
a given patient throughout the study. The CSFT was deﬁned as the
average retinal thickness of the circular area with a 1-mm diameter
around the foveal center, and the CSFV (macular volume) was
deﬁned as the average volume of the 3-mm ﬁeld centered around
the fovea. The (change in) retinal thickness was similar across
different equipment. Intraretinal ﬂuid was deﬁned and diagnosed
by the CRC as noncystoid ﬂuid (i.e., did not include cysts) on
OCT. Intraretinal cysts were deﬁned as hyporeﬂective deﬁned
spaces of 25 mm or more in any dimension within the retina on
OCT.
Fluorescein Angiography and Color Fundus Photo-
graphy. FA and 7-ﬁeld color fundus photography were performed
at screening and months 2, 6, and 12. The investigators evaluated
the FA and color fundus images for presence or absence of active
leakage per standard clinical practice and forwarded these images
to the CRC for standardized evaluation.
Treatment Exposure. Data were collected on the overall
number of ranibizumab treatments up to month 11.
Safety Assessments. Safety assessments included collection of
type, frequency, and severity of adverse events (AEs) and serious
AEs (SAEs) up to month 12.
Statistical Analysis
Assuming a standard deviation (SD) of 15 ETDRS letters for the
change in BCVA at month 2 compared with baseline, based on a
randomization ratio of 2:1, a sample size of 112 and 56 patients in
the ranibizumab and sham arms, respectively, was considered.
With this sample size, the resulting power for analysis of covari-
ance was 89.7% to detect a mean treatment difference of 8 ETDRS
letters at a 1-sided a level of 0.025. Conservative sample size
calculations were performed using the 2-sample t test.
The primary and secondary efﬁcacy outcomes were analyzed in
the full analysis set using observed data and the randomized
treatment. The full analysis set included all randomized patients to
whom treatment regimen was assigned. Hypothesis tests were
evaluated at a 1-sided signiﬁcance level of 2.5% and 2-sidedasymptotic 95% conﬁdence intervals (CIs) were reported. The
primary efﬁcacy outcome, deﬁned as the change in BCVA from
baseline to month 2, was analyzed using a mixed-effects repeated
measure model. For the subgroup analyses, a forest plot was pro-
vided. In addition, the P value for the treatment subgroup inter-
action for each subgroup was displayed. The P value was obtained
using the same model used for the primary analysis and also
including terms for the subgroup and the treatment subgroup
interaction.
Frequencies and percentages, with corresponding Clop-
perePearson exact 2-sided 95% CIs, were provided for selected
binary efﬁcacy variables. Least squares (LS) means and 95% CIs
were used to support the conclusions of statistical inferences.
Descriptive statistics included number of observations, mean, SD,
standard error (as required), median and ranges for continuous
variables, and frequencies and percentages for categorical values;
where appropriate, estimates of treatment group differences, CIs,
and P values were presented. The primary safety analysis was a
comparison between treatment arms, conducted for the period after
the ﬁrst treatment, while sham treatment was administered (day 1
to month 2). All other safety analyses (from day 1 to month 12)
were descriptivedthere were no comparisons between the treat-
ment armsdand were performed using the safety set that included
all patients who received 1 or more administrations of the study
treatment and underwent 1 or more safety assessments after
baseline. Statistical analyses were performed using SAS software
version 9.4 (SAS Institute, Cary, NC).Results
Patient Disposition and Baseline Characteristics
Of the 178 patients randomized to receive either ranibizumab
(n ¼ 118) or sham (n ¼ 60), 156 patients (87.6%) completed the
study (ranibizumab, n ¼ 106 [89.8%]; sham, n ¼ 50 [83.3%]). The
most common reasons for discontinuation were consent withdrawal
(n ¼ 7) and physician’s decision (n ¼ 6; Fig 1).
The study treatment was received by all patients in the full
analysis set (n ¼ 177). Of the 177 patients in the safety set, 119
patients and 58 patients were included in the ranibizumab and
sham arms, respectively. In the sham arm, 56 patients (97.0%)
received at least 1 ranibizumab injection at or after month 2, or at
both points. For safety analyses, patients who were assigned
initially to sham followed by open-label ranibizumab from month 2
onward were designated as ‘sham with ranibizumab’ patients (n ¼
56) and those who did not were designated as ‘sham without
ranibizumab’ patients (n ¼ 2).
Baseline patient demographics and ocular characteristics
generally were well balanced across both treatment arms. The
mean age of the patients was 62.9 years (SD, 14.50), the proportion
of men was 61.8%, and most patients (87.6%) were white
(Table 1). The baseline mean BCVA and CFST were 65.0 letters
(SD, 12.47) and 465.5 mm (SD, 141.95), respectively (Table 1).
Efﬁcacy
Best-Corrected Visual Acuity. Ranibizumab was superior in
efﬁcacy compared with sham from baseline to month 2 (LS
mean, þ5.7 letters [95% CI, 4.1e7.3] vs. þ2.9 letters [95% CI,
1.2e4.7]; 1-sided P ¼ 0.0111); hence, the primary end point was
met with a treatment effect of þ2.8 letters (Fig S2, available at
www.aaojournal.org).3
Figure 1. Diagram showing patient disposition (randomized set*). *Consisted of all patients who were randomized. AE ¼ adverse event.
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5.7 letters (95%CI, 3.96e7.35) with ranibizumab and 3.0 letters (95%
CI, 1.20e4.80) with sham. The mean gain in BCVA from baseline to
month 12 was 9.6 letters (95% CI, 7.47e11.72) and 8.7 letters (95%
CI, 5.43e11.97) in patients originally randomized to ranibizumab and
sham, respectively (Fig 2).
Across the predeﬁned baseline ME etiology subgroups, the
treatment effect (LS mean) ranged from 0.5 letters (95%
CI, 6.10 to 5.11) to þ5.9 letters (95% CI, 0.91e10.81; Fig 3). A
treatment effect of 5.86 letters and 5.45 letters was seen in
pseudophakic or aphakic subgroup and the inﬂammatory or post-
uveitis subgroup, respectively, whereas that observed in the
miscellaneous group was 3.26 letters. Insigniﬁcant treatment
effect was seen in the CSC (0.54 letters) and idiopathic (0.49
letters) subgroups.
Because of the variability in treatment effects observed across
different subgroups, analyses for other efﬁcacy variables are shown
by ME etiology only. Across baseline ME etiology, the mean
change in BCVA from baseline to month 2 ranged from þ3.0
letters to þ8.5 letters in the ranibizumab arm and þ1.0 letter
to þ4.7 letters in the sham arm. All patients received open-label
ranibizumab treatment from month 2 onward, indicated by dis-
ease activity. At month 12, the mean change in BCVA by baseline
ME etiology ranged from þ5.6 letters to þ14.5 letters in the
ranibizumab arm, whereas this was þ5.7 letters to þ10.5 letters in
patients originally assigned to the sham arm (Table 2).
In the ME miscellaneous group, the mean BCVA change at
month 2 ranged from 2.0 letters (Coats’ disease) to 25.0 letters
(pattern dystrophies of the retinal pigment epithelium), whereas at
month 12, the mean BCVA ranged from 5.0 letters (radiation
retinopathy) to 28.0 letters (pattern dystrophies of the retinal
pigment epithelium; Table S1, available at www.aaojournal.org).
Anatomic Outcomes. Overall, from baseline to month 2,
there was a higher reduction with ranibizumab compared with sham
in CRC-assessed CSFT (LS mean, 81.8 mm [95% CI, 107.54to 56.1] vs. 30.8 mm [95% CI, 58.0 to 3.6]; 1-sided P ¼
0.0037; Fig S3, available at www.aaojournal.org). At month 12, the
reductions in CRC-assessed CSFT were similar in both treatment
arms (Fig 4).
By baseline ME cause subgroups, the mean CSFT change from
baseline tomonth 2 ranged from56.3 to99.7mm in ranibizumab-
treated patients, whereas the mean change in CSFT ranged
from17.9 to51.4 mm in patients in the sham group. At month 12
in the ranibizumab arm, the mean change in CSFT ranged
from79.4 to181.7 mm and from51.5 to165.2 mm in patients
assigned to sham arm (Table 3). Changes in CSFT (assessed in the
central 1 mm area) and CSFV (assessed in the central 3 mm
volume) showed very similar trends overall and by baseline ME
etiology subgroups for the ranibizumab and sham arms.
At months 2 and 12, the proportion of patients in the ME eti-
ology subgroups showing absence of macular edema (Fig S4,
available at www.aaojournal.org), intraretinal ﬂuid (Fig S5,
available at www.aaojournal.org), cysts (Fig S6, available at
www.aaojournal.org), and subretinal ﬂuid (Fig S7, available
at www.aaojournal.org) was greater with the ranibizumab
compared with the sham arm.
Treatment Exposure
Ranibizumab Injections. Up to month 11, patients received a
mean of 6.7 ranibizumab injections (SD, 3.7) of a possible 12
injections in the ranibizumab arm versus 5.7 ranibizumab
injections (SD, 3.1) of a possible 10 injections in the ‘sham with
ranibizumab’ group. Depending on the baseline ME etiology, the
mean number of ranibizumab injections in the ranibizumab arm up
to month 11 ranged from 5.8 to 8.7; the mean number of ranibi-
zumab injections in the ‘sham with ranibizumab’ group ranged
from 4.2 to 7.0 (Table 4).
Rescue Treatment. No patients received any rescue
treatment.
Table 1. Baseline Demographic, Ocular, and Disease Characteristics (Randomized Set*)
Variables/Characteristics Ranibizumab 0.5 mg (n [ 118) Sham (n [ 60)
Total
(N [ 178)
Age, years
n 118 60 178
Mean (SD) 63.5 (13.97) 61.8 (15.55) 62.9 (14.50)
Gender, n (%)
Male 73 (61.9) 37 (61.7) 110 (61.8)
Predominant race, n (%)
White 106 (89.8) 50 (83.3) 156 (87.6)
Black 1 (0.8) 1 (1.7) 2 (1.1)
Asian 11 (9.3) 7 (11.7) 18 (10.1)
Other 0 2 (3.3) 2 (1.1)
VA (letters)
n 118 60 178
Mean (SD) 65.4 (12.73) 64.1 (12.00) 65.0 (12.47)
VA category (letters), n (%)
60 33 (28.0) 24 (40.0) 57 (32.0)
>60 85 (72.0) 36 (60.0) 121 (68.0)
IOP, mmHg
n 118 60 178
Mean (SD) 14.9 (2.90) 14.5 (2.81) 14.7 (2.87)
Baseline ME etiology, n (%)
Inﬂammatory/after uveitis 14 (11.9) 7 (11.7) 21 (11.8)
Pseudophakic/aphakic 42 (35.6) 17 (28.3) 59 (33.1)
CSC 14 (11.9) 11 (18.3) 25 (14.0)
Idiopathic 37 (31.4) 14 (23.3) 51 (28.7)
Miscellaneous 11 (9.3) 11 (18.3) 22 (12.4)
Time since diagnosis of current ocular condition, mos
n 118 60 178
Mean (SD) 3.76 (9.10) 2.36 (3.71) 3.29 (7.73)
Median 0.90 1.03 0.92
Time since diagnosis of underlying disease, mos
n 118 60 178
Mean (SD) 15.90 (31.51) 10.10 (14.05) 13.94 (27.01)
Median 4.04 4.76 4.17
CSFT, mm
n 116 60 176
Mean (SD) 466.3 (147.10) 464.0 (132.60) 465.5 (141.95)
CSFT category (mm), n (%)
<300 13 (11.0) 6 (10.0) 19 (10.7)
300e500 64 (54.2) 29 (48.3) 93 (52.2)
>500e700 31 (26.3) 24 (40.0) 55 (30.9)
>700 8 (6.8) 1 (1.7) 9 (5.1)
Missing 2 (1.7) 0 2 (1.1)
CFSV (macular volume), mLy
n 116 60 176
Mean (SD) 3.00 (0.64) 2.93 (0.59) 2.98 (0.62)
CSFV (macular volume) category (mL), n (%)
<1.8 0 1 (1.7) 1 (0.6)
1.8e3.2 81 (68.6) 43 (71.7) 124 (69.7)
>3.2e4.6 34 (28.8) 15 (25.0) 49 (27.5)
>4.6 1 (0.8) 1 (1.7) 2 (1.1)
Missing 2 (1.7) 0 2 (1.1)
CRC ¼ central reading center; CSC ¼ central serous chorioretinopathy; CSFT ¼ central subﬁeld thickness; CSFV ¼ central subﬁeld volume;
IOP ¼ intraocular pressure; ME ¼ macular edema; Mos ¼ months; SD ¼ standard deviation; VA ¼ visual acuity.
*Consisted of all patients who were randomized.
yRecorded by CRC as inner subﬁeld volume of the ﬁeld with 3-mm diameter around the foveal center.
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Serious Adverse Events. Up to month 2, 1 patient in the rani-
bizumab arm experienced an ocular SAE in the study eye (endoph-
thalmitis) that resolved within 33 days. The investigator consideredthis SAE as not suspected to be related to the ranibizumab, but rather
was related to ocular injection. Nonocular SAEs were reported in 6
patients up tomonth 2.Up tomonth 12, ocular SAEswere reported in
3 patients in the ranibizumab arm and none in the ‘sham with rani-
bizumab’ and ‘sham without ranibizumab’ groups (Table S2,5
Figure 2. Graph showing the change in best-corrected visual acuity (BCVA) from baseline to month 12 (full analysis set* [observed]). *Consisted of all
randomized patients to whom treatment regimen was assigned. CI ¼ conﬁdence interval.
Ophthalmology Volume -, Number -, Month 2017available at www.aaojournal.org). The percentage of SAEs reported
in patients assigned to the ranibizumab arm and the ‘sham with
ranibizumab’ group was similar; these SAEs primarily were the
result of nonocular events. Up to month 12, nonocular SAEs were
reported in 10.9% (13/119), 8.9% (5/56), and 50.0% (1/2) of
patients in the ranibizumab arm and ‘sham with ranibizumab’ and
‘sham without ranibizumab’ groups, respectively (Table S2,
available at www.aaojournal.org). None of the ocular or nonocular
SAEs was suspected by the investigator to be related to
ranibizumab. Up to month 12, there was 1 nonocular SAE
(presyncope) in the ranibizumab arm suspected to be related to
ocular injection. There were 3 deaths during the study
(ranibizumab, n ¼ 1; sham, n ¼ 2). Up to month 2, 1 patient died
of brain stem stroke and basilar artery thrombosis in the sham arm.
From months 2 to 12, 1 patient died in the ‘sham with
ranibizumab’ group of cardiorespiratory arrest and 1 patient died
of cerebral hemorrhage in the ranibizumab arm. None of the deaths
was considered to be related to ranibizumab and/or sham treatment.
Adverse Events. Ocular AEs were reported in 39 patients
(ranibizumab, n ¼ 33; sham, n ¼ 6) and 89 patients (ranibizumab,
n ¼ 64; sham with ranibizumab, n ¼ 25; sham withoutFigure 3. Graph showing change in best-corrected visual acuity from baseline t
*Consisted of all randomized patients to whom treatment regimen was assigned. y
that did not ﬁt into the other cause subgroups and were insufﬁciently frequent to
chorioretinopathy; ME ¼ macular edema.
6ranibizumab group, n ¼ 0) up to months 2 and 12, respectively.
Conjunctival hemorrhage (10.2%), VA reduction (7.9%), and eye
pain (6.8%) were the most frequently reported ocular AEs up to
month 12 (Table 5). Up to months 2 and 12, nonocular AEs were
reported in 34 patients (ranibizumab, n ¼ 20; sham, n ¼ 14) and 94
patients (ranibizumab, n ¼ 65; ‘sham with ranibizumab’, n ¼ 28;
‘sham without ranibizumab’, n ¼ 1), respectively. The most
frequently reported nonocular AEs up to month 12 were
nasopharyngitis (7.9%), hypertension (4.5%), and inﬂuenza
(5.1%; Table 5). Ocular and nonocular AEs suspected to be
related to ocular drug and injection up to month 12 are shown in
Tables S3 and S4, respectively (available at www.aaojournal.org).Discussion
PROMETHEUS was the ﬁrst randomized phase 3 clinical
trial that evaluated the efﬁcacy and safety of ranibizumab in
patients with ME resulting from uncommon causes, that is,
causes other than diabetic retinopathy, nAMD, or RVO.
Overall, ranibizumab demonstrated statistically signiﬁcanto month 2 in each of the speciﬁed subgroups (full analysis set* [observed]).
P value is the interaction between the subgroup and treatment. **Etiologies
form a separate subgroup. CI ¼ conﬁdence interval; CSC ¼ central serous
Table 2. Mean Best-Corrected Visual Acuity and Mean Change in Best-Corrected Visual Acuity from Baseline to Months 2 and 12 by
Baseline Macular Edema Etiology (Full Analysis Set* [Observed])
Macular Edema Etiology Ranibizumab 0.5 mg Sham
Inﬂammatory/after uveitis
Month 2
At baseline, n 13 7
Mean BCVA (95% CI) at baseline, letters 64.0 (54.91e73.09) 65.4 (60.20e70.66)
Mean BCVA (95% CI) at month 2, letters 70.2 (57.97e82.33) 66.4 (57.74e75.12)
Mean change (95% CI) from baseline, letters 6.2 (0.28e12.03) 1.0 (5.43 to 7.43)
Month 12
At baseline, n 12 6
Mean BCVA (95% CI) at baseline, letters 63.4 (53.53e73.30) 66.5 (60.88.e72.12)
Mean BCVA (95% CI) at month 12, letters 69.3 (56.16e82.50) 76.5 (69.15e83.85)
Mean change (95% CI) from baseline, letters 5.9 (0.94 to 12.78) 10.0 (1.82e18.18)
Pseudophakic/aphakic
Month 2
At baseline, n 40 16
Mean BCVA (95% CI) at baseline, letters 61.7 (58.36e65.04) 57.4 (51.79e63.08)
Mean BCVA (95% CI) at Month 2, letters 70.2 (67.19e73.21) 61.5 (55.77e67.23)
Mean change (95% CI) from baseline, letters 8.5 (5.48e11.52) 4.1 (0.55 to 8.68)
Month 12
At baseline, n 37 13
Mean BCVA (95% CI) at baseline, letters 62.1 (58.80e65.37) 57.6 (51.54e63.69)
Mean BCVA (95% CI) at Month 12, letters 76.6 (73.41e79.78) 68.2 (57.72e78.59)
Mean change (95% CI) from baseline, letters 14.5 (10.58e18.45) 10.5 (0.78e20.30)
CSC
Month 2
At baseline, n 14 11
Mean BCVA (95% CI) at baseline, letters 72.7 (66.68e78.75) 70.8 (63.34e78.29)
Mean BCVA (95% CI) at month 2, letters 75.7 (69.02e82.41) 73.3 (64.38e82.17)
Mean change (95% CI) from baseline, letters 3.0 (0.26e5.74) 2.5 (0.96 to 5.87)
Month 12
At baseline, n 14 10
Mean BCVA (95% CI) at baseline, letters 72.7 (66.68e78.75) 71.0 (62.62e79.38)
Mean BCVA (95% CI) at month 12, letters 78.4 (71.33e85.38) 77.6 (68.01e87.19)
Mean change (95% CI) from baseline, letters 5.6 (2.20e9.08) 6.6 (2.75e10.45)
Idiopathic retinopathy/retinochoroidopathy
Month 2
At baseline, n 36 14
Mean BCVA (95% CI) at baseline, letters 68.1 (64.04e72.24) 65.7 (15.17)
Mean BCVA (95% CI) at month 2, letters 71.9 (67.92e75.91) 70.4 (61.21e79.64)
Mean change (95% CI) from baseline, letters 3.8 (0.46e7.10) 4.7 (0.05 to 9.48)
Month 12
At baseline, n 32 11
Mean BCVA (95% CI) at baseline, letters 67.8 (63.16e72.40) 65.0 (53.83e76.17)
Mean BCVA (95% CI) at month 12, letters 75.5 (71.38e79.69) 75.5 (65.31e85.60)
Mean change (95% CI) from baseline, letters 7.8 (3.82e11.68) 10.5 (0.01 to 20.92)
Miscellaneous
Month 2
At baseline, n 11 11
Mean BCVA (95% CI) at baseline, letters 65.7 (58.12e73.33) 64.4 (57.31e71.42)
Mean BCVA (95% CI) at month 2, letters 70.0 (61.60e78.40) 65.5 (58.65e72.26)
Mean change (95% CI) from baseline, letters 4.3 (0.82 to 9.36) 1.1 (0.65 to 2.83)
Month 12
At baseline, n 11 10
Mean BCVA (95% CI) at baseline, letters 65.7 (58.12e73.33) 66.3 (60.04e72.56)
Mean BCVA (95% CI) at month 12, letters 73.2 (64.83e81.53) 72.0 (66.31e77.69)
Mean change (95% CI) from baseline, letters 7.5 (0.95e13.96) 5.7 (2.70e8.70)
BCVA ¼ best-corrected visual acuity; CI ¼ conﬁdence interval; CSC ¼ central serous chorioretinopathy.
*Consisted of all randomized patients to whom treatment regimen was assigned.
Staurenghi et al  Ranibizumab for ME of Uncommon Causessuperiority to sham at month 2 in improving BCVA; thus,
the primary study end point was met. However, the overall
treatment effect of þ2.8 ETDRS letters at 2 months wasconsidered to be of low clinical relevance. Nevertheless,
with ranibizumab treatment until month 11, patients origi-
nally assigned to ranibizumab or sham treatment gained 9.67
Figure 4. Graph showing change in central subﬁeld thickness (CSFT) from baseline to month 12 (full analysis set* [observed]). *Consisted of all ran-
domized patients to whom treatment regimen was assigned. CI ¼ conﬁdence interval.
Ophthalmology Volume -, Number -, Month 2017and 8.7 letters versus baseline, respectively, at month 12.
The 2-month treatment effect was variable across different
ME etiology subgroups from a gain of more than 5 letters to
a loss of 0.5 letter on average. The limited treatment effect
may have been caused in part by a longer time since diag-
nosis and a lower proportion of patients with lower baseline
VA (60 letters) in the ranibizumab arm (3.76 months and
28.0%, respectively) compared with the sham arm (2.36
months and 40.0%, respectively). The eligibility require-
ment of a diagnosis no less than 3 months before study entry
was implemented in a protocol amendment, as was ME with
a high likelihood of spontaneous resolution (e.g., CSC or
pseudophakic ME) unless the persistent ME was introduced
as an exclusion criterion in the amendment. By then, how-
ever, most patients were enrolled into the study; hence, the
amendment had a minor impact on the enrolled patients. The
higher potential of self-resolution in these ME conditions2,37
and the higher potential to gain more with lower baseline
BCVA may have contributed to a smaller treatment effect.
Similarly to the observations from this study, variable
treatment effects of anti-VEGF agents in patients with ME
resulting from different uncommon causes have been
described from previous smaller trials and case
reports.2,3,7,25e29,32,36,37
In PROMETHEUS, a greater treatment effect at month 2
was achieved with ranibizumab in the inﬂammatory or
post-uveitis subgroup (treatment effect of 5.45 letters; 14
patients received ranibizumab and 7 patients received sham
treatment). The letter gain in the ranibizumab arm was
maintained up to month 12 (5.9 letters). Sham-treated pa-
tients gained less than 1 letter on average up to month 2, but
gained 10 letters at month 12 (after treatment with ranibi-
zumab as of month 2 [n ¼ 6]). The pseudophakic or aphakic
subgroup showed a clinically important treatment effect of
5.86 letters at month 2 (41 patients received ranibizumab
and 17 patients received sham treatment). In the8sham-treated patients, spontaneous VA recovery up to
month 2 was 3.2 letters (vs. 9.1 letters for ranibizumab-
treated patients). At month 12, patients treated with ranibi-
zumab from baseline had gained 14.5 letters, whereas pa-
tients originally treated with sham and eligible for
ranibizumab treatment from month 2 gained 10.5 letters.
The observed treatment effects in patients in the inﬂam-
matory or post-uveitis group and the pseudophakic or
aphakic group in PROMETHEUS are consistent with the
ﬁndings in similar subgroups reported previously with anti-
VEGF agents.7,25e29,32,36
For the subgroup of patients with ME resulting from
CSC, the treatment effect at month 2 was negligible (þ0.54
letters; 14 patients received ranibizumab and 11 patients
received sham treatment). Previous publications have shown
that patients with CSC have a high spontaneous rate of
resolution of ME38e41 and consequently have a good visual
prognosis. Currently, the preferred method of treatment in
these patients is observation followed by off-label vPDT in
cases without spontaneous resolution.39e41 The role of
VEGF in the pathogenesis of CSC is ambiguous, and pre-
vious ﬁndings have suggested that CSC could be entirely
independent of VEGF.8,39e42 In a small pilot study, patients
with CSC when treated with unlicensed bevacizumab
showed signiﬁcantly less VA gain compared with those
treated with off-label vPDT.34 Although one previous study
has reported higher VEGF levels in the aqueous humor of
patients with CSC responding to bevacizumab treatment
versus nonresponders,33 the absence of any signiﬁcant
treatment effect with ranibizumab in patients with CSC in
PROMETHEUS supports the assumption that CSC may
not be driven by VEGF. In PROMETHEUS, CSC patients
treated with ranibizumab recovered 3.0 letters of BCVA
over 2 months, whereas sham-treated patients recovered
2.5 letters. However, it is important to point out that patients
with choroidal neovascularization resulting from CSC have
Table 3. Mean Central Subﬁeld Thickness and Mean Change in Central Subﬁeld Thickness from Baseline to Months 2 and 12 by
Baseline Macular Edema Etiology (Full Analysis Set* [observed])
Macular Edema Cause Ranibizumab 0.5 mg Sham
Inﬂammatory/post-uveitis
Month 2
At baseline, n 14 7
Mean CSFT (95% CI) at baseline, mm 545.6 (527.89663.40) 504.1 (387.00621.28)
Mean CSFT (95% CI) at month 2, mm 450.5 (313.14587.86) 452.7 (328.82576.61)
Mean change (95% CI) from baseline, mm 95.1 (197.17 to 6.88) 51.4 (194.82 to 91.97)
Month 12
At baseline, n 12 7
Mean CSFT (95% CI) at baseline, mm 538.1 (397.94678.23) 504.1 (387.00621.28)
Mean CSFT (95% CI) at month 12, mm 444.0 (317.64570.36) 390.7 (274.09507.34)
Mean change (95% CI) from baseline, mm 94.1 (172.65 to 15.52) 113.4 (281.69 to 54.84)
Pseudophakic/aphakic
Month 2
At baseline, n 39 16
Mean CSFT (95% CI) at baseline, mm 520.1 (479.12560.98) 547.8 (484.68610.94)
Mean CSFT (95% CI) at month 2, mm 420.4 (370.26470.51) 511.1 (435.69586.43)
Mean change (95% CI) from baseline, mm 99.7 (156.05 to 43.28) 36.8 (87.05 to 13.55)
Month 12
At baseline, n 35 12
Mean CSFT (95% CI) at baseline, mm 51.7.7 (472.52562.97) 554.4 (468.71640.12)
Mean CSFT (95% CI) at month 12, mm 336.0 (303.48e368.52) 389.3 (289.28489.22)
Mean change (95% CI) from baseline, mm 181.7 (231.33 to 132.16) 165.2 (285.25 to 45.08)
CSC
Month 2
At baseline, n 13 11
Mean CSFT (95% CI) at baseline, mm 362.0 (311.48412.52) 400.4 (321.41479.32)
Mean CSFT (95% CI) at month 2, mm 305.7 (260.52350.87) 371.4 (293.75448.98)
Mean change (95% CI) from baseline, mm 56.3 (110.43 to 2.18) 29.0 (99.69 to 41.69)
Month 12
At baseline, n 13 10
Mean CSFT (95% CI) at baseline, mm 362.0 (311.48412.52) 401.3 (312.71489.89)
Mean CSFT (95% CI) at month 12, mm 282.6 (245.36319.87) 288.6 (243.21333.99)
Mean change (95% CI) from baseline, mm 79.4 (119.72 to 39.05) 112.7 (205.10 to 20.30)
Idiopathic retinopathy/retinochoroidopathy
Month 2
At baseline, n 35 14
Mean CSFT (95% CI) at baseline, mm 422.3 (381.33463.24) 448.4 (377.69519.16)
Mean CSFT (95% CI) at month 2, mm 347.7 (295.58399.79) 423.9 (338.03509.82)
Mean change (95% CI) from baseline, mm 74.6 (112.59 to 36.61) 24.5 (94.93 to 45.93)
Month 12
At baseline, n 32 11
Mean CSFT (95% CI) at baseline, mm 421.8 (378.24465.32) 442.4 (361.37523.35)
Mean CSFT (95% CI) at month 12, mm 335.3 (282.92387.77) 313.0 (255.46370.54)
Mean change (95% CI) from baseline, mm 86.4 (128.22 to 44.66) 129.4 (191.87 to 66.86)
Miscellaneous
Month 2
At baseline, n 11 11
Mean CSFT (95% CI) at baseline, mm 424.8 (352.43497.20) 396.6 (307.91485.36)
Mean CSFT (95% CI) at month 2, mm 362.7 (273.32452.13) 378.7 (287.23470.22)
Mean change (95% CI) from baseline, mm 62.1 (122.21 to 1.97) 17.9 (51.17 to 15.35)
Month 12
At baseline, n 11 10
Mean CSFT (95% CI) at baseline, mm 424.8 (352.43497.20) 374.6 (291.66457.54)
Mean CSFT (95% CI) at month 12, mm 318.1 (261.77374.41) 323.1 (253.90392.30)
Mean change (95% CI) from baseline, mm 106.7 (148.17 to 65.29) 51.5 (94.21 to 8.79)
CI ¼ conﬁdence interval; CSC ¼ central serous chorioretinopathy; CSFT ¼ central subﬁeld thickness.
*Consisted of all randomized patients to whom treatment regimen was assigned.
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Table 4. Treatment Exposure up to Month 11 by Baseline
Macular Edema Etiology Subgroup (Safety Set*)
Macular Edema Etiology Subgroup
Ranibizumab
0.5 mg Sham
Inﬂammatory/post-uveitis
n 14 6
Total 99 35
Mean (SD) 7.1 (4.2) 5.8 (3.0)
Pseudophakic/aphakic
n 41 16
Total 239 67
Mean (SD) 5.8 (3.9) 4.2 (2.8)
CSC
n 15 10
Total 114 70
Mean (SD) 7.6 (2.9) 7.0 (3.5)
Idiopathic retinopathy/retinochoroidopathy
n 37 14
Total 247 82
Mean (SD) 6.7 (3.5) 5.9 (3.0)
Miscellaneous
n 12 10
Total 104 64
Mean (SD) 8.7 (3.5) 6.4 (2.7)
CSC ¼ central serous chorioretinopathy; SD ¼ standard deviation.
*Consisted of all adult patients who received at least 1 application of study
treatment and had at least 1 safety assessment after baseline.
Ophthalmology Volume -, Number -, Month 2017shown to beneﬁt from anti-VEGF treatment.43 Currently in
the European Union, ranibizumab 0.5 mg is approved for
the treatment of visual impairment resulting from
choroidal neovascularization (regardless of the underlying
etiology) in adult patients.43,44
Because of a lack of a differential diagnosis, it was not
possible to assess the reason for lack of treatment effect ofTable 5. Ocular (Study Eye) and Nonocular Adverse Events (at Le
Relationship (S
Preferred Term, n (%)
Ranibizumab
0.5 mg (n [ 119)
Sham with Ra
0.5 mg (n
Ocular AEs, total 64 (53.8) 25 (44
Conjunctival hemorrhage 11 (9.2) 7 (12
VA reduced 11 (9.2) 3 (5.4
Eye pain 10 (8.4) 2 (3.6
ME 7 (5.9) 2 (3.6
Cystoid ME 6 (5.0) 0
Dry eye 6 (5.0) 1 (1.8
IOP increased 6 (5.0) 3 (5.4
Nonocular AEs, total 65 (54.6) 28 (50
Nasopharyngitis 12 (10.1) 2 (3.6
Hypertension 6 (5.0) 2 (3.6
Inﬂuenza 6 (5.0) 3 (5.4
Basilar artery thrombosis 0 0
Brain stem stroke 0 0
AE ¼ adverse event; IOP ¼ intraocular pressure; ME ¼ macular edema; VA ¼
Preferred terms that occurred in 5% in any arm of the safety set are included in
the ranibizumab 0.5 mg arm. A patient with multiple occurrences of a preferred t
parentheses represents the number of patients and the numbers inside the brac
*Consisted of all adult patients who received at least 1 application of study tre
10anti-VEGF in the subgroup with idiopathic disease (ocular
vascular disorder, n ¼ 1; idiopathic chorioretinopathy, n ¼
36) at month 2, which represented 29% of the patients. The
overall treatment effect at the primary end point showed no
beneﬁt for ranibizumab versus sham (0.49 letters; 37 pa-
tients received ranibizumab and 14 patients received sham
treatment). At month 2, patients treated with ranibizumab
had a gain of 3.9 letters, whereas sham-treated patients
gained 4.4 letters. At month 12, the ranibizumab arm
(n ¼ 32) gained 7.8 letters and the sham arm (n ¼ 11)
gained 10.5 letters. Despite the small sample size in the
subgroup, the result indicates a self-resolving nature of this
disease and the unknown role of VEGF in its pathologic
characteristics.
The miscellaneous subgroup in the PROMETHEUS
study comprised patients whose disease resulted from
various baseline etiologies (Coats’ disease, Eales disease,
macular telangiectasia types 1 and 2, Best disease, pattern
dystrophies of the retinal pigment epithelium, trauma, ra-
diation retinopathy, and retinitis pigmentosa) that could not
be grouped under other speciﬁc ME subgroup. This sub-
group showed a small treatment effect of 3.3 letters at month
2. At months 2 and 12, the highest BCVA gain was seen in
the pattern dystrophies of the retinal pigment epithelium in 1
patient (25.0 letters and 28.0 letters, respectively). Small
case studies have reported that anti-VEGF agents combined
with laser photocoagulation may be an effective option for
the treatment of adult-onset Coat’s disease and recurrent
vitreous hemorrhage resulting from Eales disease.45e47
The same magnitude of effect size that was observed in
BCVA by baseline etiology subgroups was observed with
CSFT and CSFV, with the highest reduction observed in the
pseudophakic or aphakic subgroup at month 12
(CSFT, 181.7 mm; CSFV, 0.64 mL); at month 12, the
least reduction was observed in the CSC subgroupast 5% in Any Arm) up to Month 12 Regardless of Study Drug
afety Set*)
nibizumab
[ 56)
Sham without Ranibizumab
0.5 mg (n [ 2) Total (N [ 177)
.6) 0 89 (50.3)
.5) 0 18 (10.2)
) 0 14 (7.9)
) 0 12 (6.8)
) 0 9 (5.1)
0 6 (3.4)
) 0 7 (4.0)
) 0 9 (5.1)
.0) 1 (50.0) 94 (53.1)
) 0 14 (7.9)
) 0 8 (4.5)
) 0 9 (5.1)
1 (50.0) 1 (0.6)
1 (50.0) 1 (0.6)
visual acuity.
this summary. Preferred terms are sorted in descending order of frequency of
erm is counted only once in the preferred term row. The number outside the
kets represent the percentage.
atment and had at least 1 safety assessment after baseline.
Staurenghi et al  Ranibizumab for ME of Uncommon Causes(CSFT, 79.4 mm; CSFV, 0.27 mL). The CSFT changes
(assessed in the central 1 mm) and CSFV changes (assessed
in the central 3 mm) showed very comparable proﬁles across
causes and overall, indicating that the assessment of a larger
ﬁeld did not add any relevant information.
With respect to safety, ranibizumab was well tolerated in
the study and there were no new safety ﬁndings up to month
12. Over 12 months, 3 deaths occurred that were not related
to ranibizumab treatment. One case of endophthalmitis
occurred that resolved spontaneously within 33 days and
was not related to ranibizumab. The safety ﬁndings of
ranibizumab in PROMETHEUS were in line with the
established safety proﬁle of ranibizumab reported previ-
ously in DME, nAMD, and RVO.13,14,16,18e24,48,49
The PROMETHEUS study had certain limitations.
Before protocol amendment, the study allowed for enroll-
ment of pathologic causes of ME that may have had a high
likelihood of spontaneous resolution or for which the role of
VEGF was unclear (e.g., CSC or nonrecurrent acute ME).
Hence, the protocol was amended to exclude patients with
ocular diseases known to resolve spontaneously, those in
which the use of anti-VEGF agents was controversial, or
both. In approximately 29% of the enrolled ME cases, the
condition was deemed idiopathic; that is, in these patients,
the pathologic mechanisms leading to ME remained un-
known. Although relevant treatment effects were observed
in 2 etiology subgroups, the respective number of patients
was too small to draw clear conclusions on the treatment
beneﬁt of ranibizumab. Finally, to avoid potential under-
treatment, the comparison versus sham had to be limited to
month 2. This meant that any long-term treatment effects
versus sham could not be analyzed. To conclude, although
patients with ME resulting from inﬂammatory conditions or
post-uveitis and patients with ME occurring after cataract
surgery seem to beneﬁt from ranibizumab treatment, rani-
bizumab treatment seems to have no beneﬁt in ME resulting
from CSC. For idiopathic ME, a more exploratory approach
needs to be followed.
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